CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the consent form (or your guardian can if you’re 17 or younger).
- You are between 2 and 70 years old.
- Your diagnosis is CD19-positive non-Hodgkin lymphoma or ALL confirmed by tests on tissue or cells.
- Your doctor has evidence of measurable disease (PET/CT findings for lymphoma, or measurable leukemia in blood or bone marrow).
- You’ve already had at least 2 prior drug treatments for your cancer, and you can’t get a standard curative treatment.
- You can safely participate: your energy level is good enough (ECOG 0–2 or similar), and your kidney and liver tests are within allowed limits.
- You can provide a tumor tissue sample for extra lab testing (archived is okay).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially trained to find and kill cancer cells that have a protein called CD19 on them. It is for patients whose leukemia or lymphoma has come back or not gone away after standard treatments.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Hear when a new Relapsed Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.